Scienture Holdings Management

Management criteria checks 0/4

Scienture Holdings' CEO is Shankar Hariharan, appointed in May 2025, has a tenure of 1.08 years. total yearly compensation is $1.31M, comprised of 17.8% salary and 82.2% bonuses, including company stock and options. directly owns 9.57% of the company’s shares, worth $1.49M. The average tenure of the management team and the board of directors is 1.2 years and 2 years respectively.

Key information

Shankar Hariharan

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	17.80%
CEO tenure	1.1yrs
CEO ownership	9.6%
Management average tenure	1.2yrs
Board average tenure	2yrs

Recent management updates

Recent updates

Analysis Article • Jul 03

Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

CEO Compensation Analysis

How has Shankar Hariharan's remuneration changed compared to Scienture Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$42m
Dec 31 2025	US$1m	US$233k	-US$42m

Compensation vs Market: Shankar's total compensation ($USD1.31M) is above average for companies of similar size in the US market ($USD640.99K).

Compensation vs Earnings: Insufficient data to compare Shankar's compensation with company performance.

CEO

Shankar Hariharan (69 yo)

1.1yrs

Tenure

US$1,310,199

Compensation

Dr. Shankar Hariharan, Ph D., founded and served as President, Chief Executive Officer and Director of TRxADE HEALTH, Inc. (formerly known as Scienture Inc.). He is Founder and serves as Director of Scient...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shankar Hariharan	Founder	1.1yrs	US$1.31m	9.57% $ 1.5m
Narasimhan Mani	President	1.1yrs	US$1.48m	7.25% $ 1.1m
Rahul Surana	Executive VP & COO of Scienture LLC	1.8yrs	no data	no data
Michele Rath	Senior VP & Chief Commercial Officer of Scienture LLC	1.3yrs	no data	no data

1.2yrs

Average Tenure

Experienced Management: SCNX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Shankar Hariharan	Founder	1.9yrs	US$1.31m	9.57% $ 1.5m
Narasimhan Mani	President	1.1yrs	US$1.48m	7.25% $ 1.1m
Lawrence Olanoff	Member of Scientific Advisory Board	no data	no data	no data
Suneel Gupta	Member of Scientific Advisory Board	no data	no data	no data
Donald Fell	Independent Director	12.4yrs	US$307.77k	0.80% $ 124.8k
Wantanee Phuapradit	Member of Scientific Advisory Board	no data	no data	no data
Mayur Doshi	Independent Director	2.1yrs	US$384.40k	1.05% $ 162.5k
Subbarao Jayanthi	Independent Director	2yrs	US$184.40k	0.49% $ 76.3k

2.0yrs

Average Tenure

67yo

Average Age

Experienced Board: SCNX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/22 12:59
End of Day Share Price	2026/06/22 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scienture Holdings, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Nazibur Rahman	Maxim Group

Scienture Holdings Management

Management criteria checks 0/4

Key information

Recent management updates

Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026

High number of new and inexperienced directors

Scienture Holdings, Inc., Annual General Meeting, Mar 10, 2025

Scienture Holdings, Inc. Announces Director Resignations

Trxade Health, Inc. and Scienture, LLC Announces Executive Changes

No independent directors

Recent updates

Scienture Holdings Expands Arbli Payor Coverage and Commercial Access

Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026

First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.33 loss in 1Q 2025)

Full year 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Scienture Broadens Commercial Access for Rezenopy, Highest-Dose Fda-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching over 5,000 U.S. Institutions

Scienture Provides Commercial Update on ARBLI , the First FDA-Approved Ready-To-Use Oral Suspension of Losartan Potassium

Scienture and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli, the First FDA-Approved Ready-To-Use Oral Suspension of Losartan Potassium

Third quarter 2025 earnings released: US$0.19 loss per share (vs US$1.34 loss in 3Q 2024)

Scienture Holdings, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Scienture's Arbli Becomes First FDA-Approved Ready-To-Use Liquid Losartan Available Through Major U.S. Wholesalers

Scienture Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $3.87 million.

Scienture Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3.87 million.

New major risk - Share price stability

Scienture Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $21.739125 million.

Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly?

High number of new and inexperienced directors

New major risk - Market cap size

Full year 2024 earnings released: US$5.41 loss per share (vs US$0.45 loss in FY 2023)

New major risk - Share price stability

Scienture Holdings, Inc., Annual General Meeting, Mar 10, 2025

Scienture Holdings, Inc. Announces Director Resignations

Scienture Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $21.739125 million.

New major risk - Financial data availability

Trxade Health, Inc. and Scienture, LLC Announces Executive Changes

No independent directors

Scienture Inc. acquired TRxADE HEALTH, Inc. (NasdaqCM:MEDS) in a reverse merger transaction in a transaction valued at $103 Million.

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

CEO Compensation Analysis

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources